Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Cooper, Matthew J ^a,b   Cox, Nathan J ^a   Zimmerman, Eric I ^a   Dewar, Brian J ^a   Duncan, James S ^a   Whittle, Martin C ^a   Nguyen, Thien A ^a   Jones, Lauren S ^a   Ghose Roy, Sreerupa ^a   Smalley, David M ^a   Kuan, Pei Fen ^b,c   Richards, Kristy L ^a,b   Christopherson, Richard I ^d   Jin, Jian ^e   Frye, Stephen V ^e   Johnson, Gary L ^a,b   Baldwin, Albert S ^a,b   Graves, Lee M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ATM PROTEIN; CELL PROTEIN; I KAPPA B KINASE ALPHA; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JANUS KINASE; KIT PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MULTIPLEXED KINASE INHIBITOR BEAD; PHOSPHOTRANSFERASE; PROTEIN KINASE; PROTEIN KINASE C BETA; PROTEIN KINASE LYN; PROTEIN KINASE YES; UNCLASSIFIED DRUG; BCR ABL PROTEIN; BENZAMIDE DERIVATIVE; DASATINIB; LYN PROTEIN-TYROSINE KINASE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL LOSS; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA; MASS SPECTROMETRY; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; AFFINITY CHROMATOGRAPHY; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BENZAMIDES; CELL LINE; CELL SURVIVAL; CHROMATOGRAPHY, AFFINITY; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOBLOTTING; LEUKEMIA; NF-KAPPA B; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SRC-FAMILY KINASES; THIAZOLES;

EID: 84879474335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066755     Document Type: Article

References (83)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566 doi:10.1038/nm0596-561.
2. Druker BJ, (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30 doi:10.1016/S0065-230X(04)91001-9.
3. Hochhaus A, Schenk T, Erben P, Ernst T, La Rosée P, et al. (2009) Cause and management of therapy resistance. Best Pract Res Clin Haematol 22: 367-379 doi:10.1016/j.beha.2009.05.004.
4. Mauro MJ (2006) Defining and managing imatinib resistance. Hematology Am Soc Hematol Educ Program: 219-225. doi:10.1182/asheducation-2006.1.219.
5. Ault P, (2007) Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Clin J Oncol Nurs 11: 125-129 doi:10.1188/07.CJON.125-129.
6. Barouch-Bentov R, Sauer K, (2011) Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs 20: 153-208 doi:10.1517/13543784.2011.546344.
7. Mian A, Schüll M, Zhao Z, Oancea C, Hundertmark A, et al. (2009) The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL. Leukemia 23: 1614-1621 doi:10.1038/leu.2009.69.
8. Quintás-Cardama A, Cortes J, (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113: 1619-1630 doi:10.1182/blood-2008-03-144790.
9. Hochhaus A, La Rosée P, Müller MC, Ernst T, Cross NCPP, (2011) Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 10: 250-260 doi:10.4161/cc.10.2.14537.
10. White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, et al. (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108: 697-704 doi:10.1182/blood-2005-11-4687.
11. Engler JR, Frede A, Saunders V a, Zannettino a CW, Hughes TP, et al. (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24: 765-770 doi:10.1038/leu.2010.16.
12. Burger H, Van Tol H, Boersma AWM, Brok M, Wiemer EAC, et al. (2004) Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942 doi:10.1182/blood-2004-04-1398.
13. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, et al. (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18: 401-408 doi:10.1038/sj.leu.2403257.
14. O'Dwyer ME, Mauro MJ, Kurilik G, Mori M, Balleisen S, et al. (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 100: 1628-1633 doi:10.1182/blood-2002-03-0777.
15. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, et al. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16: 2190-2196 doi:10.1038/sj.leu.2402741.
16. Lee F, Fandi A, Voi M, (2008) Overcoming kinase resistance in chronic myeloid leukemia. Int J Biochem Cell Biol 40: 334-343 doi:10.1016/j.biocel.2007.10.001.
17. Burchert A, Wang Y, Cai D, Von Bubnoff N, Paschka P, et al. (2005) Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782 doi:10.1038/sj.leu.2403898.
18. Grosso S, Puissant A, Dufies M, Colosetti P, Jacquel A, et al. (2009) Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors. Mol Cancer Ther 8: 1924-1933 doi:10.1158/1535-7163.MCT-09-0168.
19. Nishioka C, Ikezoe T, Yang J, Yokoyama A, (2010) Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 24: 1631-1640 doi:10.1038/leu.2010.145.
20. Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, et al. (2010) Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Res 70: 9659-9670 doi:10.1158/0008-5472.CAN-10-2034.
21. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101: 690-698 doi:10.1182/blood.V101.2.690.
22. Ito T, Tanaka H, Kimura A, (2007) Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 78: 417-431 doi:10.1111/j.1600-0609.2007.00835.x.
23. Wu J, Meng F, Lu H, Kong L, Bornmann W, et al. (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood 111: 3821-3829 doi:10.1182/blood-2007-08-109330.
24. Pene-Dumitrescu T, Peterson LF, Donato NJ, Smithgall TE, (2008) An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene 27: 7055-7069 doi:10.1038/onc.2008.330.
25. Hayette S, Chabane K, Michallet M, Michallat E, Cony-Makhoul P, et al. (2011) Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res 35: 38-43 doi:10.1016/j.leukres.2010.06.030.
26. Walters DK, Goss VL, Stoffregen EP, Gu T-L, Lee K, et al. (2006) Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res 30: 1097-1104 doi:10.1016/j.leukres.2006.01.001.
27. Zhu F, Wang Y, Zeng S, Fu X, Wang L, et al. (2009) Involvement of annexin A1 in multidrug resistance of K562/ADR cells identified by the proteomic study. OMICS 13: 467-476 doi:10.1089/omi.2009.0046.
28. Pocaly M, Lagarde V, Etienne G, Dupouy M, Lapaillerie D, et al. (2008) Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. Proteomics 8: 2394-2406 doi:10.1002/pmic.200701035.
29. Gu T, Nardone J, Wang Y, Loriaux M, Villén J, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6: e19169 doi:10.1371/journal.pone.0019169.
30. Daub H, Olsen J V, Bairlein M, Gnad F, Oppermann FS, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31: 438-448 doi:10.1016/j.molcel.2008.07.007.
31. Oppermann FS, Gnad F, Olsen J V, Hornberger R, Greff Z, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8: 1751-1764 doi:10.1074/mcp.M800588-MCP200.
32. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132 doi:10.1038/nbt1358.
33. Breitkopf SB, Oppermann FS, Keri G, Grammel M, Daub H, (2010) Proteomics analysis of cellular imatinib targets and their candidate downstream effectors. J Proteome Res 9: 6033-6043 doi:10.1021/pr1008527.
34. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, et al. (2011) In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 18: 699-710 doi:10.1016/j.chembiol.2011.04.011.
35. Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, et al. (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149: 307-321 doi:10.1016/j.cell.2012.02.053.
36. Bantscheff M, Hopf C, Kruse U, Drewes G, (2007) Proteomics-Based Strategies in Kinase Drug Discovery. 3: 1-28 doi:10.1007/2789.
37. Wissing J, Jänsch L, Nimtz M, Dieterich G, Hornberger R, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6: 537-547 doi:10.1074/mcp.T600062-MCP200.
38. Unwin RD, Griffiths JR, Whetton AD, (2010) Simultaneous analysis of relative protein expression levels across multiple samples using iTRAQ isobaric tags with 2D nano LC-MS/MS. Nat Protoc 5: 1574-1582 doi:10.1038/nprot.2010.123.
39. Ow SY, Salim M, Noirel J, Evans C, Rehman I, et al. (2009) iTRAQ underestimation in simple and complex mixtures: "the good, the bad and the ugly". J Proteome Res 8: 5347-5355 doi:10.1021/pr900634c.
40. Karp NA, Huber W, Sadowski PG, Charles PD, Hester S V, et al. (2010) Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics 9: 1885-1897 doi:10.1074/mcp.M900628-MCP200.
41. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57: 289-300.
42. Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R, (1995) The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med 181: 1827-1834.
43. Saijo K, Mecklenbräuker I, Santana A, Leitger M, Schmedt C, et al. (2002) Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med 195: 1647-1652 doi:10.1084/jem.20020408.
44. Saijo K, Schmedt C, Su I-H, Karasuyama H, Lowell CA, et al. (2003) Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immunol 4: 274-279 doi:10.1038/ni893.
45. Scapini P, Pereira S, Zhang H, Lowell C a, (2009) Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 228: 23-40 doi:10.1111/j.1600-065X.2008.00758.x.
46. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401 doi:10.1126/science.1099480.
47. Nam S, Kim D, Cheng JQ, Zhang S, Lee J-H, et al. (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185-9189 doi:10.1158/0008-5472.CAN-05-1731.
48. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, et al. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 104: 13283-13288 doi:10.1073/pnas.0702654104.
49. Inohara N, Koseki T, Lin J, Del Peso L, Lucas PC, et al. (2000) An induced proximity model for NF-kappa B activation in the Nod1/RICK and RIP signaling pathways. J Biol Chem 275: 27823-27831 doi:10.1074/jbc.M003415200.
50. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, et al. (2001) CARD4/Nod1 mediates NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO Rep 2: 736-742 doi:10.1093/embo-reports/kve155.
51. Dan HC, Adli M, Baldwin AS, (2007) Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res 67: 6263-6269 doi:10.1158/0008-5472.CAN-07-1232.
52. Comb WC, Cogswell P, Sitcheran R, Baldwin AS, (2011) IKK-dependent, NF-κB-independent control of autophagic gene expression. Oncogene 30: 1727-1732 doi:10.1038/onc.2010.553.
53. Comb WC, Hutti JE, Cogswell P, Cantley LC, Baldwin AS, (2012) p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol Cell 45: 719-730 doi:10.1016/j.molcel.2012.01.010.
54. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, et al. (2003) A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423: 659-663 doi:10.1038/nature01648.
55. Hoberg JE, Yeung F, Mayo MW, (2004) SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell 16: 245-255 doi:10.1016/j.molcel.2004.10.010.
56. Park K-J, Krishnan V, O'Malley BW, Yamamoto Y, Gaynor RB, (2005) Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. Mol Cell 18: 71-82 doi:10.1016/j.molcel.2005.03.006.
57. Yamamoto Y, Verma UN, Prajapati S, Kwak Y-T, Gaynor RB, (2003) Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423: 655-659 doi:10.1038/nature01576.
58. Oeckinghaus A, Ghosh S, (2009) The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1: a000034 doi:10.1101/cshperspect.a000034.
59. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, et al. (2005) A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145: 178-192 doi:10.1038/sj.bjp.0706176.
60. Sano M, Fukuda K, Sato T, Kawaguchi H, Suematsu M, et al. (2001) ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 89: 661-669.
61. Chou T-C, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
62. Chou T-C, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681 doi:10.1124/pr.58.3.10.
63. Chou T-C, (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70: 440-446 doi:10.1158/0008-5472.CAN-09-1947.
64. Katagiri K, Yokoyama KK, Yamamoto T, Omura S, Irie S, et al. (1996) Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. J Biol Chem 271: 11557-11562.
65. Ketley NJ, Allen PD, Kelsey SM, Newland AC, (2000) Mechanisms of resistance to apoptosis in human AML blasts: the role of differentiation-induced perturbations of cell-cycle checkpoints. Leukemia 14: 620-628.
66. Vondrácek J, Sheard MA, Krejcí P, Minksová K, Hofmanová J, et al. (2001) Modulation of death receptor-mediated apoptosis in differentiating human myeloid leukemia HL-60 cells. J Leukoc Biol 69: 794-802.
67. Camarasa MV, Castro-Galache MD, Carrasco-García E, Garcia-Morales P, Saceda M, et al. (2005) Differentiation and drug resistance relationships in leukemia cells. J Cell Biochem 94: 98-108 doi:10.1002/jcb.20278.
68. O'Hare T, Eide CA, Deininger MW, (2008) Persistent LYN signaling in imatinib-resistant, BCR-ABL-independent chronic myelogenous leukemia. J Natl Cancer Inst 100: 908-909 doi:10.1093/jnci/djn204.
69. Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, et al. (2010) Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Mol Pharmacol 78: 811-817 doi:10.1124/mol.110.066258.
70. Ingley E, (2008) Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784: 56-65 doi:10.1016/j.bbapap.2007.08.012.
71. Wang Q, Zimmerman EI, Toutchkine A, Martin TD, Graves LM, et al. (2010) Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia. ACS Chem Biol 5: 887-895 doi:10.1021/cb100099h.
72. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, et al. (2002) Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci U S A 99: 4465-4470 doi:10.1073/pnas.012025199.
73. Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, et al. (2011) Targeting PKC-mediated signal transduction pathways using enzastaurin to promote apoptosis in acute myeloid leukemia-derived cell lines and blast cells. J Cell Biochem 112: 1696-1707 doi:10.1002/jcb.23090.
74. Wu Z, Doondeea JB, Gholami AM, Janning MC, Lemeer S, et al. (2011) Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics 10: M111.011635 doi:10.1074/mcp.M111.011635.
75. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, et al. (2001) ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2: 222-228 doi:10.1093/embo-reports/kve046.
76. Liu J, Lin A, (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15: 36-42 doi:10.1038/sj.cr.7290262.
77. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, et al. (1997) Interaction between ATM protein and c-Abl in response to DNA damage. Nature 387: 520-523 doi:10.1038/387520a0.
78. Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, et al. (2009) Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res 69: 9337-9345 doi:10.1158/0008-5472.CAN-09-0548.
79. Bassères DS, Baldwin AS, (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817-6830 doi:10.1038/sj.onc.1209942.
80. Duncan EA, Goetz CA, Stein SJ, Mayo KJ, Skaggs BJ, et al. (2008) IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther 7: 391-397 doi:10.1158/1535-7163.MCT-07-0305.
81. Bednarski BK, Baldwin AS, Kim HJ, (2009) Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One 4: e6992 doi:10.1371/journal.pone.0006992.
82. Pratilas CA, Solit DB, (2010) Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 16: 3329-3334 doi:10.1158/1078-0432.CCR-09-3064.
83. Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, et al. (2011) Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Mol Cancer Ther 10: 1581-1590 doi:10.1158/1535-7163.MCT-10-1033.